Muscle relaxants in vaginismus management

Obstetrics & Gynaecology
Vaginismus is a genitopelvic pain and penetration disorder characterised by involuntary tightening of the pelvic floor muscles during attempted vaginal penetration, whether during sexual intercourse, tampon insertion or gynaecological examination. It may cause pain, discomfort or an inability to achieve penetration, significantly affecting sexual function, reproductive healthcare and quality of life. The condition is often associated with anticipatory anxiety, fear of pain and increased pelvic floor muscle activity, making management challenging and requiring a sensitive, individualised approach. Treatment generally involves a multidisciplinary strategy, including pelvic floor physiotherapy, psychosexual therapy and gradual desensitisation techniques. Muscle relaxants have also been explored as an adjunctive treatment to reduce pelvic floor muscle hypertonicity and facilitate penetration. However, their role in clinical practice remains under investigation, and they should be considered alongside, rather than as a replacement for, established therapeutic approaches.[1]Role of muscle relaxants in vaginismusMuscle relaxants have been explored for pelvic floor muscle spasm because reducing excessive muscular activity may theoretically improve relaxation and penetration toleranceHowever, clinical evidence supporting the routine use of pharmacological muscle relaxants specifically for vaginismus remains insufficient[3]The National Institute for Health and Care Excellence (NICE) recommends against offering intravaginal Diazepam for pelvic floor dysfunction because available evidence has not demonstrated adequate clinical benefit and concerns remain regarding dependence[2]Therefore, no specific oral or intravaginal muscle relaxant can currently be recommended as standard pharmacological treatment for vaginismusPharmacological treatment should not replace interventions addressing pelvic floor dysfunction, psychological contributors, and penetration-related fearClinical assessment and treatment selectionA detailed clinical history should evaluate penetration-related pain, involuntary muscle tightening, previous traumatic experiences, sexual difficulties, and associated psychological distressPelvic examination, with the patient's consent, should assess pelvic floor muscle tone, tenderness, involuntary contraction, and associated musculoskeletal abnormalitiesAlternative causes of painful penetration, including vulvodynia, vulvovaginal infections, endometriosis, and genitourinary syndrome of menopause, should be evaluated[3]Treatment selection should consider symptom severity, contributing psychological factors, patient preferences, and associated pelvic floor dysfunctionEvidence-based therapeutic approachesPelvic floor physiotherapy: Specialized physiotherapy focuses on muscle relaxation, manual therapy, biofeedback, and improving voluntary control of pelvic floor activityGraduated vaginal dilator therapy: Progressive exposure to appropriately sized vaginal dilators helps improve tolerance of vaginal insertion and reduce penetration-related fearCognitive behavioral therapy: Psychological interventions address anticipatory anxiety, fear of penetration, avoidance behaviors, and negative associations with sexual activityPsychosexual counseling: Counseling helps address emotional distress, relationship difficulties, and sexual concerns associated with vaginismusRelaxation techniques: Breathing exercises, mindfulness, and guided pelvic floor relaxation can help patients develop greater awareness and control of involuntary muscular responses[3]Clinical considerations and treatment monitoringPatients should receive clear information about the limited evidence supporting pharmacological muscle relaxants and the availability of established nonpharmacological treatmentsTreatment progress should be assessed through improvements in pelvic floor relaxation, pain, penetration tolerance, sexual function, and psychological well-beingPersistent symptoms should prompt reassessment of the diagnosis, associated pain conditions, treatment adherence, and contributing psychological factorsA multidisciplinary approach involving gynecologists, pelvic floor physical therapists, and mental health professionals can support individualized management[2][3]Parameters for evaluating treatment responseAssessment parameterClinical significancePelvic floor muscle toneHelps identify persistent muscular hypertonicity.Pain intensityEvaluates changes in penetration-related discomfort.Patient-reported sexual functionAssesses the effect of treatment on sexual health and quality of life.Psychological distressIdentifies persistent anxiety and fear associated with penetration.Patient satisfactionEvaluates treatment acceptability and individual therapeutic goals.ConclusionAlthough muscle relaxants have been considered for reducing pelvic floor muscle hypertonicity, current evidence does not support their routine use in vaginismus management. In particular, intravaginal Diazepam is not recommended by NICE for pelvic floor dysfunction. Pelvic floor physiotherapy, graduated vaginal dilator therapy, relaxation techniques, and psychosexual interventions remain central to treatment. Individualized assessment and multidisciplinary care are essential for improving symptoms and restoring sexual function.[2][3]Reference(s):1. Wicaksono RA, Gunawan E, Fitriansari S, Pacik PT, Tjandraprawira KD. Managing Vaginismus with Assisted Dilatation Multidisciplinary Protocol - Retrospective Cohort Study from Indonesia's Largest Dedicated Centre. Int J Womens Health. 2026;18:580236. Published 2026 Mar 11. doi:10.2147/IJWH.S580236. https://pmc.ncbi.nlm.nih.gov/articles/PMC12990243/2. National Institute for Health and Care Excellence. Pelvic Floor Dysfunction: Prevention and Non-surgical Management. NICE Guideline NG210. Published December 9, 2021. Accessed November 11, 2026. https://www.nice.org.uk/guidance/ng2103. Melnik T, Hawton K, McGuire H. Interventions for vaginismus. Cochrane Database Syst Rev. 2012;12(12):CD001760. Published 2012 Dec 12. doi:10.1002/14651858.CD001760.pub2. https://pmc.ncbi.nlm.nih.gov/articles/PMC7072531/